Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

NCT04940286 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Borderline Resectable Pancreatic Adenocarcinoma
Resectable Pancreatic Adenocarcinoma
Stage IA Pancreatic Cancer AJCC v8
Stage IB Pancreatic Cancer AJCC v8
Stage IIA Pancreatic Cancer AJCC v8
Stage IIB Pancreatic Cancer AJCC v8

Interventions

BIOLOGICAL: Durvalumab
DRUG: Gemcitabine
DRUG: Nab-paclitaxel
BIOLOGICAL: Oleclumab

Sponsor

M.D. Anderson Cancer Center